Hence, the assessment of the level of FISH+CD34+CD38- cells at diagnosis could help clinicians to identify patients as an effective prognostic indicator in AML with recurrent chromosomal abnormalities, eg. CBF-AML (Data not shown), and thereby refining the selection of therapeutic strategies and, possibly, long-term clinical outcome. This evidence concerns the gene CEBPZ and acute myeloid leukemia.